Figure 3.
Decitabine and tazemetostat activated transcription of antigen-presentation genes in DLBCL cell lines. (A-F) SUDHL-6 and DB cells were treated with indicated drugs (decitabine, 100 nM; tazemetostat, 1 μM; IFN-γ, 10 ng/mL). Graph of fold-change in transcript to untreated for each indicated gene (panels A, D) B2M, (panels B, E) Tap1, (panels C, F) Tap2. Mean ± SD is shown for 3 technical replicates per 2 biological replicates. *P < .05; **P < .01; ****P < .0001.

Decitabine and tazemetostat activated transcription of antigen-presentation genes in DLBCL cell lines. (A-F) SUDHL-6 and DB cells were treated with indicated drugs (decitabine, 100 nM; tazemetostat, 1 μM; IFN-γ, 10 ng/mL). Graph of fold-change in transcript to untreated for each indicated gene (panels A, D) B2M, (panels B, E) Tap1, (panels C, F) Tap2. Mean ± SD is shown for 3 technical replicates per 2 biological replicates. *P < .05; **P < .01; ****P < .0001.

Close Modal

or Create an Account

Close Modal
Close Modal